Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369966 · ClinicalTrials.gov registry record
Brain Circuits in Schizophrenia and Smoking
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 42
- Enrollment target
NCT01369966: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01369966 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01369966 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Background: \- Smoking is associated with serious health risks. People who have mental illness are more likely to smoke. Researchers are studying the brain circuits linked with smoking and nicotine craving. This study will look at whether a specific brain circuit can explain the high rate of smoking in people with schizophrenia. Objectives: \- To study brain activity in smokers and nonsmokers with and without schizophrenia, as well as their family members. Eligibility: * Current smokers (at least 100 cigarettes in the past year) and nonsmokers between 18 and 62 years of age in one of the following groups: * Have been diagnosed with schizophrenia. * Family members of those with schizophrenia. * Healthy adults with no history of severe mental illness or brain trauma. * Family members of the healthy adults. Design: * People in the study will be screened with a physical exam, medical history, questionnaires, and blood tests. * They will have up to three visits: the screening visit and two study visits (each given 1 year apart). * At the first study visit, those taking part will be trained in the tests they will do during the magnetic resonance imaging (MRI) scan. Then they will have the MRI scan. * After the first study visit, current smokers will receive phone calls from the study researchers every other month for 1 year. They will be asked about their smoking habits. * At the second study visit, current smokers and some nonsmokers will have another MRI scan and the same tests as before. * Current smokers will receive a final phone call 1 year after the second study visit. They will be asked to give information about their smoking habits.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-05-16 |
| Est. Completion | 2014-12-24 |
What the finished NCT01369966 record still lists
NCT01369966 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01369966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01369966 about?
NCT01369966 is a clinical study titled "Brain Circuits in Schizophrenia and Smoking". Background: \- Smoking is associated with serious health risks. People who have mental illness are more likely to smoke. Researchers are studying the brain circuits linked with smoking and nicotine craving. This study will look at whether a specific brain circuit can explain the high rate of smokin...
What is the current status of trial NCT01369966?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2011-05-16. Estimated completion is 2014-12-24.
Who is sponsoring clinical trial NCT01369966?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI